Company intelligence / Profile preview

Inimmune Corporation

Missoula, Montana, United Statesfacebook.com ↗

Ownership: Private
Employees: ~50
Development stage: Phase 1

Overview

Successfully completed Phase 1 clinical trial for intranasal INI-2004 for allergic rhinitis, which was safe and well-tolerated with no drug-related serious adverse events and showed dose-related improvement in nasal congestion compared to placebo. Currently enrolling patients in Phase 1 oncology clinical trial using INI-4001 (TLR7/8) monotherapy in a nanoparticle formulation[4].

Therapeutic areas: OncologyImmunologyPsychiatryInfectious Diseases
Modalities: ImmunotherapeuticsVaccine adjuvants
Industry: Biotech

Drug pipeline

4 assets

INI-2004

3 more assets in the full pipeline.

Request access →

Partnerships

SPI Pharma, Inc. (strategic collaboration to develop and commercialize advanced adjuvant systems for vaccine development)[3][4]

Beyond the preview

Go deeper on Inimmune Corporation.

Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from trial design and recruitment through results.

Trial phase
Status
Readouts

Licensing & deals

Explore licensing agreements, acquisitions, and the assets behind each deal.

Partners
Deal terms
Milestones

Funding history

Trace financing activity and the investors behind a company’s development.

Funding rounds
Investors
Capital raised

Competitive landscape

Compare peer pipelines by target, modality, and therapeutic area.

Peer companies
Targets
Pipeline overlap

Technologies & patents

Explore technology platforms and the patent landscape around relevant assets.

Platforms
Patents
Assignees

Research & analysis

Connect company news and source material to the questions you’re investigating.

Company news
Sources
Analysis

Bring the full picture into focus.

See how Gosset can support your research on Inimmune Corporation.

Explore the full profile